ATP-R13 / Atopia Therapeutics - LARVOL DELTA

Atopia Therapeutics Reports Preclinical Proof-of-Concept of Lead Compound ATPR13 in Atopic Dermatitis and Strengthens Patent Protection (Atopia Press Release) - "As part of its ongoing development program, Atopia evaluated the effect of orally administered ATP-R13. In total, 56 mice were included in the study, assessing the efficacy of ATP-R13 compared to dexamethasone (a validated anti-inflammatory corticosteroid positive control) on local skin inflammation in the well-established ovalbumin-induced atopic dermatitis mouse model...The Company’s composition of-matter patent application covering ATP-R13 has received a positive International Preliminary Report on Patentability (IPRP) under the Patent Cooperation Treaty (PCT). This favorable assessment from the European Patent Office significantly enhances the likelihood of patent grant across the jurisdictions applied for and extends the potential patent protection for ATP-R13 until 2043."

Patent • Preclinical • Atopic Dermatitis